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Abstract. The present study aimed to elucidate the role of 
marine collagen peptides (MCPs) in protection of carotid 
artery vascular endothelial cells (CAVECs) in type 2 diabetes 
mellitus (T2DM), and the mechanism underlying this process. 
In an in vivo experiment, diabetic Wistar rats were divided 
randomly into four groups (n=10/group): Diabetes control, 
and three diabetes groups administered low, medium and 
high doses of MCPs (2.25, 4.5 and 9.0 g/kg body weight/day, 
respectively). Another 10 healthy rats served as the control. 
In an in vitro experiment, human umbilical-vein endothe-
lial cells (HUVECs) were incubated in normal and high 
concentrations of glucose with or without MCPs (3.0, 15.0 
and 30.0 mg/ml, respectively) for 24, 48 or 72 h. Blood 
vessel/endothelial construction, inflammatory exudation and 
associated molecular biomarkers in CAVECs were detected 
and analyzed. The results of the present study demonstrated 
that in rats, MCP treatment for 4 weeks significantly lowered 
blood glucose and attenuated endothelial thinning and inflam-
matory exudation in carotid-artery vascular endothelial cells. 
In vitro, the high‑glucose intervention significantly increased 
cell apoptosis in HUVECs, and medium and high doses 
of MCPs (4.5 and 9.0 g/kg body weight/day, respectively) 
partially ameliorated this high glucose-mediated apoptosis 
and decreased levels of apoptosis biomarkers. In conclusion, 
a moderate oral MCP dose (≥4.5 g/kg body weight/day) may 
be a novel therapeutic tool to protect against early cardio-
vascular complications associated with T2DM by inhibiting 
apoptosis and reducing the expression of coupling factor 6 and 
microparticles.
Introduction
Type 2 diabetes mellitus (T2DM) is a complex metabolic 
disease. Nearly 422 million adults worldwide had diabetes in 
2014, compared with 108 million in 1980. The global (age-stan-
dardized) prevalence of diabetes in the adult population has 
nearly doubled since 1980, from 4.7 to 8.5% (1). Diabetes 
caused 1.5 million mortalities in 2012. Higher-than-optimal 
blood glucose levels contributed to an additional 2.2 million 
deaths by increasing the risks of cardiovascular and other 
diseases (2). Cardiovascular disease (CVD) is a common and 
serious complication of T2DM, and is linked to increased 
mortality (3,4). The underlying mechanisms of vascular 
complications observed in patients with T2DM, as a result 
from complex interactions between metabolic, inflammatory, 
and genetic causes and atherothrombotic disease through 
diverse mechanisms, remain to be fully elucidated (5,6). 
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Therefore, the introduction of novel therapies to reduce the 
side effects of drugs or minimize the potential harm to arterial 
vascular endothelial cells induced by high glucose and blood 
lipid levels would be of great significance.
Bioactive peptides from marine sources form an attrac-
tive and promising pool of drug candidates. Marine collagen 
peptides (MCPs) have been reported to inhibit the activity 
of angiotensin I-converting enzyme (7), and to demonstrate 
antihypertensive and hyperlipidemic bioactivity (8). Our 
previous studies have demonstrated that MCP treatment can 
inhibit inflammation and oxidative stress and protect β-cells in 
pancreatic islets from apoptosis in rats with T2DM induced by 
a high-fat diet (9-11). We also revealed that MCP supplements 
may have beneficial effects on glucose and lipid metabo-
lism, insulin sensitivity, renal function and hypertension 
management in Chinese patients with T2DM and hyperten-
sion (12-15). However, the underlying mechanisms remain 
poorly understand.
More recently, links have been established between the 
expression of coupling factor 6 (CF6) and microparticles 
(MPs) in hypertension, DM and coronary heart disease. CF6 
is released from vascular endothelial cells and binds to the β 
subunit of the plasma membrane-bound adenosine triphos-
phate (ATP) synthase in these cells, leading to intracellular 
acidosis (16). CF6 produces vasoconstriction, and its biologi-
cally active site is located in the C-terminal portion. CF6 
also suppresses prostacyclin generation via the inhibition of 
cytosolic phospholipase A2, and inhibits nitric oxide synthase 
activity via an increase in asymmetrical dimethylarginine and 
a decrease in platelet/endothelial cell adhesion molecule-1. 
Thus, CF6 likely contributes to the pathogenesis of CVD (17).
MPs are present in the circulation of healthy individuals. 
They are cell membrane-derived particles that can stimulate 
coagulation, inflammation and angiogenesis, and are involved 
in cell-to-cell communication (18,19). MPs are released from 
various cell types following inflammation activation or apop-
tosis. Elevated circulating MP levels are found in patients 
with various diseases, including acute coronary syndromes, 
peripheral arterial disease, systemic inflammatory states and 
T2DM (18,20).
Our previous experiments indicated that a short-term 
MCP intervention improved cardiac systolic function to a 
certain extent in patients with hypertension (21), but the role 
of MCPs in protecting against early T2DM-associated damage 
to cardiovascular endothelial cells remains unknown. The 
present study aimed to evaluate the role of MCPs in protecting 
against T2DM-associated injury of cardiovascular endothelial 
cells in vivo and in vitro, and the mechanism underlying this 
process.
Materials and methods
Preparation and identification of MCPs. MCPs were derived 
from the skin of wild-caught chum salmon [average body 
weight (BW) 1.47 kg], which were donated by CF Haishi 
Biotechnology Ltd. Co. (Beijing, China). The MCPs were 
prepared and identified according to a method described 
previously (12,22,23). In brief, the skin of chum salmon was 
first homogenized and emulsified in distilled water. Second, 
at 40˚C and pH 8, complex protease (Alcalase® 2.4 L, 
Protamex®; Novozymes, Bagsvaerd, Denmark) was added for 
3 h before inactivation and sterile filtration. Lastly, the MCP 
mixture was powdered by spray drying. High-performance 
liquid chromatography (Waters Corporation, Milford, MA, 
USA), LDI-1700 matrix-assisted laser desorption/ioniza-
tion time‑of‑flight (MALDI‑TOF) mass spectrometry and 
H835-50 automatic amino acid analysis (Hitachi, Ltd., 
Tokyo, Japan) were used to determine the molecular weight 
distribution and amino acid composition. In addition, MCPs 
were demonstrated to contain very little or no carbohydrate 
by negative staining of the polyacrylamide gel with periodic 
acid-Schiff reagent.
Animal groups and treatments. Adult male Wistar rats (weight, 
160-180 g; age, 6 weeks; n=60) obtained from the Department 
of Animal Service of Shandong University Health Science 
Center (Shandong, China) were used for the experiment. The 
protocol followed the Institutional and National Guidelines 
for the Care and use of Animals, and the Animal Ethics 
Review Committee of Southern Medical University Health 
Science Center (Shenzhen, China) approved all experimental 
procedures involving animals for this study. The rats were 
housed individually in rooms with controlled environmental 
conditions (12‑h light/dark cycle, temperature ~25±2˚C, 50% 
humidity) in an approved animal facility, after a 1-week 
adaptation period with free access to tap water and standard 
chow diet (SCD). Rats were assigned randomly to two groups: 
Normal control (N) group (n=10) and the high-cholesterol, 
high-fat diet (HCHFD) -induced diabetes model group (n=50).
Experimental design and T2DM rat model. T2DM was 
induced according to methods described in our previous 
study (18). After 2 weeks of HCHFD feeding, freshly prepared, 
intraperitoneally-injected streptozotocin (STZ, 30 mg/kg BW) 
in citrate buffer (0.1 M, pH 4.5) was administered 3 times 
a week. At 1-2 weeks later, fasting blood glucose (FBG) of 
rats were detected by a blood glucose meter, and 45 rats with 
FBG levels ≥11.1 mmol/l were considered as T2DM and were 
used for the experiment. A total of 40 of these diabetic rats 
were then assigned randomly to 4 groups treated with vehicle 
(group D), or 2.25 (low dose, group L), 4.5 (medium dose, 
group M) or 9.0 (high dose, group H) g/kg BW/day MCPs 
(n=10/group) (24). The MCPs and vehicle (distilled water; 
total volume was 1 ml/application) were administered intra-
gastrically every morning after the T2DM model had been 
established for 4 weeks.
The same amount of drinking water served as the blank 
control (group N, n=10). All food and water intake was 
measured daily, and BW was measured weekly throughout the 
study.
The composition of the HCHFD (g/100 g food) was: 31% 
beef tallow, 25% cornstarch, 15.4% casein (78% protein), 8.3% 
maltodextrin, 6.3% sucrose, 5.0% cellulose, 4% corn oil, 3.5% 
mineral premix, 1% vitamin premix, 0.3% L-cysteine and 
0.2% choline bitartrate. Sucrose solution (30%) was provided 
as drinking fluid to HCHFD-fed rats. The SCD contained 
47% cornstarch, 14.2% maltodextrin, 7% corn oil, no beef 
tallow, and the same percentages of other ingredients as the 
HCHFD. SCD-fed rats were provided normal drinking water. 
Mineral and vitamin mixtures purchased from Harlan Teklad 
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(Madison, WI, USA) were fed to all rats (25). Rats receiving 
and not receiving STZ continued on their original diets for the 
duration of the study.
At days 0 and 28 after treatment, blood samples were 
collected by retro-orbital sinus puncture under chloroform 
anesthesia (80-95% chloroform gas; flow rate, 20 ml/min; 
Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). FBG 
levels were determined using a glucometer. The flow chart of 
the study is presented in Fig. 1.
Isolation, culture and treatment of human umbilical‑vein 
endothelial cells (HUVECS). HUVECs (cat. no. #8000; 
ScienCell Research Laboratories, Inc., Carlsbad, CA, USA) 
were collected as described previously (26). They were 
cultured in HuMedia supplemented with 10% fetal bovine 
serum (Sigma-Aldrich; Merck KGaA), 10 ng/ml recombinant 
epidermal growth factor, 1 ng/ml hydrocortisone, 5 ng/ml 
recombinant fibroblast growth factor and 10 ng/ml heparin 
under 5% CO2 at 37˚C. HUVECs were incubated in a normal 
glucose concentration (1,000 mg/l, group N), or high glucose 
concentration (4,000 mg/l, group D) without or with MCPs 
[3.0 mg/ml (group L), 15.0 mg/ml (group M) or 30.0 mg/ml 
(group H)] for 24, 48 or 72 h. The dose of MCPs in group H 
was calculated based on the following formula: typical clinical 
dose (2.25 g/kg) x standard adult male BW (60 kg)]/average 
blood volume (4,500 ml). The doses in groups M and L 
were one‑fifth and one‑tenth those in group H, respectively. 
Cholecystokinin-octopeptide assays were performed to assess 
cell growth inhibition using a cell counting kit-8 (Dojindo 
Molecular Technologies, Inc., Kumamoto, Japan), which were 
detected using an ELISA microplate reader (LabSystems 
Multiskan MS 352; Thermo Fisher Scientific, Inc.), and the 
growth inhibition ratio was calculated using the formula: 
Growth inhibition ratio=[normal control optical density (OD) 
values-treatment group OD values]/normal control OD values 
x100%.
Histological analysis. Histological analysis was performed 
as described previously (27). At 4 weeks after HCHFD treat-
ment and MCP interventions, all rats were sacrificed following 
anesthesia with Fentanyl (0.4 mg/kg; Sigma-Aldrich; Merck 
KGaA) and carotid artery vascular endothelial cells (CAVECs) 
were collected. CAVECs were fixed in 4% phosphate‑buffered 
saline-buffered formalin for >24 h, followed by processing 
for conventional paraffin embedding. Sections (5‑um thick-
ness) were mounted on glass slides, dewaxed, rehydrated with 
distilled water and stained with hematoxylin and eosin. The 
CAVECs were examined using a light microscope to identify 
pathological changes.
Biochemical analysis. After 28 days of treatment and before 
sacrifice for organ collection, the animals were fasted overnight 
and weighed, and blood samples were then collected by heart 
puncture using a needle under chloroform anesthesia (80-95% 
chloroform gas; flow rate, 20 ml/min; Sigma‑Aldrich; Merck 
KGaA). Two different tubes with and without anticoagulant 
(heparin) were used for blood collection in each rat to obtain 
serum and plasma. Following this, serum and plasma were 
prepared by centrifuging the blood samples at 1,200 x g and 
4˚C for 10 min. Plasma glucose levels were estimated using 
a glucose oxidase activity assay kit (Sigma-Aldrich; Merck 
KGaA), with a semi-automated analyzer (Photometer 5010 
V5+; RIELE GmbH & Co KG, Berlin, Germany).
ELISA. Using ELISA kits, the levels of biomarkers including 
CF6, epithelial membrane proteins (EMPs), peroxisome prolif-
erator-activated receptor γ (PPARγ; cat. no. CK-CK-E30647H), 
factor related apoptosis (Fas; cat. no. CK-E076217H), soluble 
factor-related apoptosis ligand (sFASL; cat. no. CK-E076218H) 
and MPs (cat. no. CK-E39822R) in plasma, CAVEC and 
HUVEC culture supernatants were measured using ELISA 
kits according to the manufacturer's protocol (R&D Systems, 
Inc., Minneapolis, MN, USA) as described previously (28,29). 
All samples and standards were evaluated in triplicate to 
ensure the accuracy of results.
Flow cytometric analysis of HUVEC apoptosis biomarkers 
with Annexin V‑fluorescein isothiocyanate (FITC). Cells were 
labeled with Annexin V-FITC (IQP Products BV, Groningen, 
The Netherlands) and propidium iodide (PI; donated by 
Dr. E. Reits, Department of Cell Biology and Histology, 
Academic Medical Centre, Amsterdam-Zuidoost, The 
Netherlands). Samples were analyzed and cell numbers per 
culture flask were estimated using flow cytometry (Beckman 
Coulter Epics XL; Beckman Coulter, Inc., Brea, CA, USA) and 
Cell Quest software v4.7.0 (BD Biosciences, Franklin Lakes, 
NJ, USA).
Reverse transcription‑quantitative polymerase chain reac‑
tion (RT‑qPCR). Total RNA was extracted from HUVECs 
using TRIzol reagent (Life Technologies; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA). RT‑qPCR was performed 
according to the protocol supplied with the TaqMan Gold 
RT‑PCR kit (Applied Biosystems; Thermo Fisher Scientific, 
Inc.). Oligonucleotide primers and Taq-Man probes for CF6, 
EMPs, caspase-3, caspase-8 and Fas were designed using 
Primer Express version 1.5 (Applied Biosystems; Thermo 
Fisher Scientific, Inc.). The final reaction volume was 25 µl and 
the thermocycling conditions for qPCR were as follows: initial 
Figure 1. The protocol of present study. BW, body weight; SCD, standard 
chow diet; HCHF, high-cholesterol high-fat; FBG, fasting blood glucose; 
MCPs, marine collagen particles; STZ, streptozotocin.
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Table I. Fasting blood glucose values before and after MCP interventions in rats with T2DM induced by a high-carbohydrate, 
high-fat diet.
  Baseline FBG  Post-intervention FBG
Group (n=10 each) (tail blood, mmol/l) Pa (heart blood, mmol/l) Pa
N 6.27±0.98 - 5.64±0.51 -
D 25.00±3.84 <0.0001 24.70±4.30 <0.0001
L 23.42±3.65 <0.0001 24.56±2.85 <0.0001
M 22.80±3.05 <0.0001 21.00±4.53 <0.0001b
H 22.33±3.10 <0.0001 20.97±1.69 <0.0001c
Data are presented as the mean ± standard deviation. at-test.; bP=0.021, M vs. D. cP=0.013, H vs. D. FBG, fasting blood glucose; MCP, marine 
collagen peptide; T2DM, type II diabetes mellitus; N, control group; D, diabetes model group, treated with vehicle only; L, low-dose group; 
M, medium-dose group; H, high-dose group.
Figure 2. (A) Histological characteristics of CAVECs in the five groups after MCP intervention, as assessed by hematoxylin and eosin staining (magnifica-
tion, x400). Levels of (B) PPARγ, (C) CF6 and (D) MP in CAVECs, and levels of (E) CF6 and (F) MPs in plasma. Data are presented as the mean ± standard 
deviation. CAVECs, carotid artery vascular endothelial cells; CF6, coupling factor 6; MP, microparticles; PPARγ, peroxisome proliferator-activated receptor 
γ; MCPs, marine collagen peptides.
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denaturation at 94˚C for 3 min, then 30 cycles of 94˚C for 30 sec, 
55˚C for 30 sec and 72˚C for 1 min, and a final extension of 72˚C 
for 10 min. The forward and reverse primers for qPCR were as 
follows: β-actin, forward, GTG GGG CGC CCC AGG CAG GCA 
CCA and reverse, CTC CTT AAT GTC ACG CAC GAT TTC 
(540 bp); Fas, forward, GGA CCC AGA ATA CCA AGT GC and 
reverse, GCC ACT GTT TCA GGA TTT AAG G (238 bp); sFasL, 
forward, CCT TGG TAG GAT TGG GCC TG and reverse, GTT 
GCA AGA TTG ACC CCG GA (304 bp); caspase-8, forward, 
GGA CAG GAA TGG AAC ACA CTT and reverse, TCA GGA 
TGG TGA GAA TAT CAT C (557 bp); caspase-3, forward, TTT 
TTC AGA GGG GAT CGT TG and reverse, TCA AGC TTG TCG 
GCA TAC TG (296 bp; Biosune); PPARγ, forward, CAC CTC 
GGT CTC CCC AGA and reverse, TCA ATT GCC ATG AGG 
GAG TTG GAA, (529 bp); CF6 forward, GCC CCA ATC CGC 
TTT GTT TT and reverse, CAC CAC CTC CGC TCT ACT TC 
(408 bp); and EMPs, forward, CAC CGG AGG GAC ACT TAT 
GG, and reverse, CGC ACA CAG AGG GTG TGT AT (200 bp). 
Values were averaged from duplicate data and normalized with 
human β-actin by the 2-ΔΔCq method (30).
Statistical analysis. All data are expressed as the mean ± stan-
dard deviation, and the significance of differences between 
experimental and control values were examined using one-way 
analysis of variance and a least significant difference post‑hoc 
test for multiple comparisons. SPSS 18.0 software (SPSS Inc., 
Chicago, IL, USA) was used to perform analyses. P<0.05 was 
considered to indicate a statistically significant difference.
Results
Effects of diets on blood glucose levels. FBG levels were 
significantly higher in HCHFD‑fed rats (groups D, L, M, and 
H) compared with SCD-fed rats (group N; all P<0.05; Table I). 
Baseline FBG levels were significantly higher in groups D, L, 
M and H than in group N. After 4 weeks of MCP interventions, 
FBG levels were significantly lower in groups M and H than in 
group D (21.00±4.53 and 20.97±1.69 vs. 24.70±4.30 mmol/l; 
P=0.021 and 0.013, respectively; Table I).
Effects of MCPs on CAVECs, CF6, MPs and PPARγ in vivo. 
CAVECs from rats in groups D, L, M and H exhibited different 
degrees of endothelial thinning and inflammatory exudation. 
MCP interventions partly inhibited the inflammatory response 
in CAVECs; this effect was most pronounced in group H 
(Fig. 2A).
Furthermore, PPARγ levels in CAVECs were significantly 
reduced in groups D, L and M compared with group N (all 
P<0.001). PPARγ levels were reduced in group H compared 
with group N, but this difference was not significant, suggesting 
that high-dose MCPs improved the expression of PPARγ in 
CAVECs (Fig. 2B).
ELISA data demonstrated that CF6 levels in plasma and 
CAVECs were significantly increased in groups D, L, M and H 
than in group N (P=0.001). Furthermore, CF6 levels in plasma 
were significantly reduced in group H compared with groups 
D and L (P=0.036 and 0.015, respectively). Notably, CF6 levels 
in CAVECs were significantly reduced in groups L, M and 
H than in group D (all P<0.001), but no significant difference 
among these three groups was detected. Thus, a certain MCP 
dosage appeared to improve the diastolic function of endothe-
lial cells (Fig. 2C; Table II).
Similarly, MP levels in plasma and CAVECs were signifi-
cantly higher in groups D, L, M and H than in group N (all 
P<0.001). MP levels in plasma were significantly reduced in 
group H than in group D (P=0.002). MP levels in CAVECs 
were significantly lower in groups L, M and H compared with 
group D (all P<0.001). MP levels were significantly reduced in 
group H compared with group L (P=0.024; Fig. 2D; Table II).
Effects of MCPs on HUVEC growth in vitro. In in vitro experi-
ments, HUVECs cultured with a high glucose concentration 
demonstrated increased cell growth inhibition, particularly 
with prolonged culture (72 vs. 24 h, P<0.01; Fig. 3, Table III). 
At 24 h of culture, MCP treatment effectively reversed the inhi-
bition of cell growth (groups M and H vs. group D, P<0.05). 
The protective effect of MCPs on HUVECs was also observed 
at 72 h after MCP intervention (groups L, M and H vs. group 
D, P<0.05; Fig. 3; Table III).
Effects of MCPs on CF6, MPs and PPARγ in the supernatant 
of HUVEC cultures. In vitro experiments demonstrated that 
HUVEC CF6 (Fig. 4A) and MP (Fig. 4B) levels in supernatant 
were elevated after 48 and 72 h culture with a high glucose 
Table II. Coupling factor 6 and microparticles expression in plasma and carotid artery vascular endothelial cells in rats after MCP 
or vehicle interventiona.
Tissue Biomarker N D L M H
Plasma CF6 (pg/ml) 37.29±5.46 74.25±14.10b 75.54±9.07b 67.45±6.62b 65.74±7.08b,c
 MPs (mg/ml) 1.32±0.44 4.66±0.84b 4.15±0.82b 3.98±0.74b 3.51±0.52b,d
CAVEC CF6 (pg/mg) 10.32±2.59 47.86±4.8b 32.27±4.5b,e 28.78±3.20b,e 30.91±5.21b,e
 MPs (mg/mg) 0.27±0.08 2.46±0.55b 1.56±0.37b,e 1.52±0.51b,e 1.15±0.37b,e,f
 PPARγ (pg/mg) 11.45±0.67 7.8±0.29b 7.93±0.93b 8.04±1.13b 8.36±2.91
Data are presented as the mean ± standard deviation. at-test; bP<0.001 vs. N; cP=0.036 vs. D, P=0.015 vs. L; dP=0.002 vs. D; eP=0.001 vs. D; 
fP=0.024 vs. L. MCP, marine collagen peptide; N, control group; D, diabetes model group, treated with vehicle only; L, low-dose group; M, 
medium-dose group; H, high-dose group; MPs, microparticles; CF6, coupling factor 6; PPARγ, peroxisome proliferator-activated receptor γ; 
CAVEC, carotid artery vascular endothelial cell.
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concentration. MCP treatment significantly downregulated 
these elevated CF6 and MP levels at 48 and 72 h (P<0.05 
and P<0.01, respectively), particularly in group H, where CF6 
levels were comparable to those of group. The opposite trend 
was observed for PPARγ levels: MCP treatment significantly 
increased PPARγ in the supernatant of HUVEC culture 
in groups M and H at 72 h compared with the other groups 
(P<0.05; Fig. 4C; Table III).
Effects of MCPs on the expression of apoptosis biomarkers 
caspase‑3, caspase‑8 and Fas in HUVECs, as detected 
by RT‑qPCR. After a 72‑h cell culture, MCPs significantly 
decreased the expression of caspase-3 in HUVECs cultured 
with a high-glucose concentration, especially in groups M and 
H (Fig. 5A). High glucose decreased the level of caspase-8 in 
comparison with the control, and MCP treatment ameliorated 
this effect (Fig. 5B). Fas expression levels had a similar pattern 
to caspase-3 (Fig. 5C).
Effects of MCPs on the expression of apoptosis biomarkers 
Fas, sFASL and Annexin‑V in HUVECs, as detected by 
ELISA or flow cytometry. The expression of Fas and sFasL 
increased when exposed to high glucose (group H vs. group 
N, P<0.05; Fig. 6A and B, respectively), and this expression 
increased continuously with prolonged culture (72 vs. 24 h, 
P<0.05). Interestingly, MCPs partially restored the expression 
of Fas and sFasL at 48 and 72 h (MCP treatment groups vs. 
group D, P<0.05), although this expression remained higher 
than that observed in group N. Similarly, a high dose of MCPs 
(30.0 mg/ml) significantly decreased the high glucose‑induced 
Figure 3. Effects of MCPs on HUVEC growth after 24, 48 and 72 h. (A) HUVECs cultured with high glucose displayed increased cell growth inhibition, which 
was effectively reversed by MCP treatment. (B) Inter-group comparison of cell growth inhibition ratios at 24, 48, and 72 h. (C) Comparison of cell growth 
inhibition ratios among time points. Data are presented as the mean ± standard deviation. HUVECs, human umbilical-vein endothelial cells; CCK-8, Cell 
Counting kit-8; MCPs, marine collagen peptides.
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elevated expression of Annexin-V/PI in HUVECs (group H vs. 
group D, P<0.05; Fig. 6C; Table III).
Discussion
Our previous research demonstrated that MCPs benefit 
vasodilatation function in patients with T2DM and hyperten-
sion (8,21), and that that oligopeptides from marine salmon skin 
reduced FBG levels by downregulating T2DM-related oxida-
tive stress and inflammation in diabetic rats (11). However, the 
molecular mechanisms underlying these beneficial effects of 
MCPs have not been identified. In the present study, MCP treat-
ment for 4 weeks significantly lowered the blood glucose level 
and attenuated endothelial thinning and inflammatory exuda-
tion in CAVECs. The present study provides the first evidence 
that the inhibitory effects of MCPs on CF6 and MPs, as well as 
apoptosis-associated factors, may contribute to their protection 
of cardiovascular endothelial cells in a T2DM rat model.
Although T2DM is associated with long-term complications 
that affect the eyes, kidneys, and peripheral and autonomic 
nervous systems, CV complications, including hypertension, MI 
and stroke, are major contributors to mortality in patients with 
T2DM (31). Intensive control of blood glucose by hypoglycemic 
agents and/or insulin has been demonstrated to have long-term 
beneficial effects, reducing the risk of CVD in patients with 
DM (32). However, the development of novel tools inhibiting 
Figure 4. Effects of marine collagen peptides on CF6 and PPARγ in the supernatant of HUVEC cultures, as detected by ELISA. (A) CF6, (B) MP and 
(C) PPARγ levels in the five groups at 24, 48 or 72 h. Data are presented as the mean ± standard deviation. HUVEC, human umbilical‑vein endothelial cell; 
CF6, coupling factor 6; MP, microparticles; PPARγ, peroxisome proliferator-activated receptor γ.
Figure 5. Effects of MCPs on apoptosis biomarkers caspase-3, caspase-8 and Fas in HUVECs. The mRNA expression of (A) caspase-3, (B) caspase-8 
and (C) Fas was detected by reverse transcription-quantitative polymerase chain reaction. β-actin served as an internal control. Data are presented as the 
mean ± standard deviation. Fas, factor related apoptosis; MCPs, marine collagen peptides; HUVECs, human umbilical-vein endothelial cells.
MOLECULAR MEDICINE REPORTS  16:  3947-3957,  2017 3955
the progression in T2DM may be important for the treatment 
and prevention of diabetic CV complications. The discovery of 
novel bioactive compounds from marine sources has proceeded 
at an ever‑increasing rate since the first marine compounds 
were described in the 1980s (14). Compared with synthetic 
compounds, these natural products from marine organisms have 
larger-scale structural diversity. Because marine-derived bioac-
tive peptides have numerous health beneficial effects, including 
anti-hypertensive, -diabetes, -oxidant, -obesity and -aging 
effects, they have attracted extensive research interest (15). 
Bioactive peptides derived from marine organisms are known to 
exhibit a wide range of physiological or hormone-like biological 
activities that extend beyond their nutritional value (23). For 
example, eicosapentaenoic acid and docosahexaenoic acid, two 
major omega-3 fatty acids of marine origin, have been demon-
strated to effectively lower blood pressure (33), treat obesity (23) 
and reduce adipose inflammation (34). Furthermore, their use 
is recommended in guidelines for the management of patients 
after myocardial infarction (35). Thus, these observations on 
MCPs may support novel therapeutic applications for prevention 
CVD in patients with DM.
The most important finding of the present study was 
that MCPs exert potent protective actions on cardiovascular 
tissues, such as endothelial cells, in the T2DM rat model. 
MCPs are low-molecular-weight peptides extracted from 
collagen tissues of marine fish, including skin, bone and 
scales, which account for 30% of marine fish processing 
waste (36). Previous investigations have confirmed that these 
protein fragments are safe in animals and humans (24). We 
previously tested the therapeutic effects of MCPs in diabetic 
animals (13) and patients (10,12,21). Diabetic rats displayed 
higher levels of serum tumor necrosis factor-α, interferon-γ 
and malondialdehyde, and lower levels of serum super-
oxide dismutase and glutathione. Notably, MCP treatment 
markedly repressed these detrimental alterations in diabetic 
rats (13). Furthermore, MCPs significantly reduced blood 
levels of fasting glucose, fasting insulin, total TGs, TC, 
LDL-C, glycated hemoglobin A1c and free-fatty acids 
in patients with T2DM (12). Therefore, we concluded that 
MCP-induced improvement in metabolic dysfunction helped 
to retain regular cardiovascular function in T2DM. As 
expected, it was demonstrated that MCP treatment decreased 
blood glucose levels and attenuated endothelial thinning and 
inflammatory exudation in CAVECs in diabetic rats. These 
results suggested that the attenuation of impaired endothelial 
function is due to the prevention of high glucose exposure.
Potential molecular mechanisms underlying the protec-
tive effect of MCPs were identified in this study. First, it was 
observed that MCPs depressed the increases in CF6 levels in 
blood and CAVECs in diabetic rats. CF6 is a component of 
mitochondrial ATP synthase that induces vasoconstriction. 
Intravenous injection of CF6 peptide has been demonstrated to 
increase blood pressure, potentially by suppressing prostacyclin 
synthesis, whereas a specific neutralizing antibody against 
CF6 decreased systemic blood pressure concomitantly with 
an increase in plasma prostacyclin (37). Diabetic patients have 
been identified to have significantly increased plasma CF6 
levels, which are correlated positively with blood glucose and 
lipid levels (38). CF6 induces insulin resistance, mild glucose 
intolerance and elevated blood pressure in mice by binding to 
the plasma membrane ATP synthase [subunit of ecto-F(1)F(o) 
complex] (34). MPs are released from platelets, leukocytes and 
endothelia during their activation or death (39). Circulating MPs 
can penetrate cells, transfer antigens, affect cell gene expression 
and activate signaling pathways associated with cell prolifera-
tion, survival, adhesion and chemotaxis (40,41). Diabetic patients 
exhibit higher blood levels of MPs (9). MPs isolated from 
diabetic rats, but not those isolated from control rats, impair the 
Figure 6. Effects of MCPs on the expression of apoptosis biomarkers in HUVECs, as detected by ELISA or flow cytometry. (A) Fas, (B) sFasL and (C) Annexin‑V 
levels at 24 h, 48 h and 72 h in the five groups. sFasL, soluble factor‑related apoptosis ligand; Fas, factor related apoptosis; MCPs, marine collagen peptides; 
PI, propidium iodide; HUVECs, human umbilical-vein endothelial cells.
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endothelium-dependent relaxation induced by acetylcholine in 
rat carotid arteries by downregulating endothelial nitric oxide 
synthase and overexpressing caveolin-1 (10). Considering these 
detrimental effects of CF6 and MPs, it was hypothesized that 
the inhibitory effects of MCPs on local and blood CF6 and MP 
levels are among the mechanisms underlying the beneficial 
effects of MCPs; namely, the early protection of cardiovascular 
endothelial cells and further prevention of CVD in patients with 
T2DM. Further molecular studies are required to investigate the 
protective action of MCPs. In addition, biomarkers and tech-
niques for the early diagnosis of cardiovascular endothelial cell 
injury in T2DM are urgently required, as the complex nature 
of the disease renders early detection difficult. The expression 
levels of CF6 and MPs are highly sensitive for the diagnosis of 
early injury of cardiovascular endothelial cells in T2DM (42).
High glucose can induce reactive oxygen species and 
apoptosis in vascular endothelial cells, which may contribute 
to the development of vascular complications in T2DM. 
Intervention with HUVECs and high glucose concentrations 
significantly increases levels of apoptosis‑associated proteins, 
such as caspase-3. In the present study, medium and high doses 
of MCPs partially inhibited high glucose-mediated endo-
thelial cell apoptosis, as evidenced by the decreased levels of 
caspase-3, caspase-8, MPs, Fas, sFASL and Annexin-V staining 
in vitro, which may be attributed to the inhibition of p38/c-Jun 
N-terminal kinase and Janus kinase 2 activation and their 
natural antioxidative properties (43). Collectively, these findings 
indicate that certain dose of MCPs are potent cardiovascular 
protectors in T2DM, revealing that an inhibitory effect of MCPs 
on apoptosis-associated proteins are likely contributors to this 
protection. In addition, PPARγ has been reported to improve 
cardiovascular function and limit atherosclerosis, potentially 
by modulating lipid metabolism and ameliorating insulin resis-
tance (44,45). The results of the present study demonstrated that 
MCP treatment significantly increased PPARγ expression in the 
supernatant of HUVEC culture. The activation of PPARγ is also 
considered as a contributing factor to this protection.
In conclusion, to the best of our knowledge, the results 
of the present study provided the first evidence that MCPs 
protect against cardiovascular endothelial cell injury and 
alleviate cardiovascular dysfunction in a T2DM rat model by 
downregulating systemic and local CF6 and MP levels, and 
reduce cell apoptosis and stimulate the expression and activity 
of PPARγ. These results supported the notion that a medium 
or high oral dose of MCPs (≥4.5 g/kg BW/day) may be a novel 
therapeutic tool to protect against early cardiovascular compli-
cations associated with T2DM.
Acknowledgements
The present study was supported by the Science and 
Technology Research and Development Funds of the Shenzhen 
Science and Technology Innovation Committee (grant 
no. JCYJ20130319164732236).
References
 1. Intensive blood-glucose control with sulphonylureas or insulin 
compared with conventional treatment and risk of complications 
in patients with type 2 diabetes (UKPDS 33). UK prospective 
diabetes study (UKPDS) Group. Lancet 352: 837-853, 1998.
 2. Jornayvaz FR: News in diabetology 2015. Rev Med Suisse 12: 
30-31 2016 (In French).
 3. WHO, Global report on diabetes 2016, http://www.who.
int/diabetes/global-report/en/.
 4. Burgeiro A, Fuhrmann A, Cherian S, Espinoza D, Jarak I, 
Carvalho RA, Loureiro M, Patrício M, Antunes M and Carvalho E: 
Glucose uptake and lipid metabolism are impaired in epicardial 
adipose tissue from heart failure patients with or without diabetes. 
Am J Physiol Endocrinol Metab 310: E550-E564, 2016.
 5. Budiman-Mak E, Epstein N, Brennan M, Stuck R, Guihan M, 
Huo Z, Emanuele N and Sohn MW: Systolic blood pressure 
variability and lower extremity amputation in a non-elderly popu-
lation with diabetes. Diabetes Res Clin Pract 114: 75-82, 2016.
 6. Caporali A, Miscianinov V, Saif J and Emanueli C: MicroRNA 
transport in cardiovascular complication of diabetes. Biochim 
Biophys Acta 1861: 2111-2120, 2016.
 7. Kim SK, Ngo DH and Vo TS: Marine fish-derived bioactive 
peptides as potential antihypertensive agents. Adv Food Nutr 
Res 65: 249-260, 2012.
 8. De Luca C, Mikhal'chik EV, Suprun MV, Papacharalambous M, 
Truhanov AI and Korkina LG: Skin antiageing and systemic 
redox effects of supplementation with marine collagen peptides 
and plant-derived antioxidants: A single-blind case-control 
clinical study. Oxid Med Cell Longev 2016: 4389410, 2016.
 9. Zhu CF, Li GZ, Peng HB, Zhang F, Chen Y and Li Y: Effect 
of marine collagen peptides on markers of metabolic nuclear 
receptors in type 2 diabetic patients with/without hypertension. 
Biomed Environ Sci 23: 113-120, 2010.
10. Zhu CF, Li GZ, Peng HB, Zhang F, Chen Y and Li Y: Therapeutic 
effects of marine collagen peptides on Chinese patients with 
type 2 diabetes mellitus and primary hypertension. Am J Med 
Sci 340: 360-366, 2010.
11. Lassoued I, Mora L, Barkia A, Aristoy MC, Nasri M and 
Toldra F: Bioactive peptides identified in thornback ray skin's 
gelatin hydrolysates by proteases from Bacillus subtilis and 
Bacillus amyloliquefaciens. J Proteomics 128: 8-17, 2015.
12. Zhu CF, Li GZ, Peng HB, Zhang F, Chen Y and Li Y: Treatment 
with marine collagen peptides modulates glucose and lipid 
metabolism in Chinese patients with type 2 diabetes mellitus. 
Appl Physiol Nutr Metab 35: 797-804, 2010.
13. Zhu CF, Peng HB, Liu GQ, Zhang F and Li Y: Beneficial effects 
of oligopeptides from marine salmon skin in a rat model of type 
2 diabetes. Nutrition 26: 1014-1020, 2010.
14. Koehnke J, Mann G, Bent AF, Ludewig H, Shirran S, Botting C, 
Lebl T, Houssen WE, Jaspars M and Naismith JH: Structural 
analysis of leader peptide binding enables leader-free cyano-
bactin processing. Nat Chem Biol 11: 558-563, 2015.
15. Shakeri A and Sahebkar A: Anti-cancer products from marine 
sponges: Progress and promise. Recent Pat Drug Deliv Formul 9: 
187-188, 2015.
16. Iba T, Aihara K, Yamada A, Nagayama M, Tabe Y and Ohsaka A: 
Rivaroxaban attenuates leukocyte adhesion in the microvascula-
ture and thrombus formation in an experimental mouse model of 
type 2 diabetes mellitus. Thromb Res 133: 276-280, 2014.
17. Osanai T, Magota K and Okumura K: Coupling factor 6 as a 
novel vasoactive and proatherogenic peptide in vascular endothe-
lial cells. Naunyn Schmiedebergs Arch Pharmacol 380: 205-214, 
2009.
18. Ishida K, Taguchi K, Hida M, Watanabe S, Kawano K, Matsumoto T, 
Hattori Y and Kobayashi T: Circulating microparticles from 
diabetic rats impair endothelial function and regulate endothelial 
protein expression. Acta Physiol (Oxf) 216: 211-220, 2016.
19. Souza AC, Yuen PS and Star RA: Microparticles: Markers and 
mediators of sepsis-induced microvascular dysfunction, immu-
nosuppression, and AKI. Kidney Int 87: 1100-1108, 2015.
20. Trzepizur W, Martinez MC, Priou P, Andriantsitohaina R and 
Gagnadoux F: Microparticles and vascular dysfunction in 
obstructive sleep apnoea. Eur Respir J 44: 207-216, 2014.
21. Zhu CF, Zhu F and Zhou JX: The intervention effect of marine 
collagen peptide on atherosclerosis,cardiac structure and cardiac 
function in hypertension patients. Chin J Gerontol 33: 1741-1744, 
2013.
22. Ko SC and Jeon YJ: Marine peptides for preventing metabolic 
syndrome. Curr Protein Pept Sci 14: 183-188, 2013.
23. Vaughan LK, Wiener HW, Aslibekyan S, Allison DB, Havel PJ, 
Stanhope KL, O'Brien DM, Hopkins SE, Lemas DJ, Boyer BB 
and Tiwari HK: Linkage and association analysis of obesity traits 
reveals novel loci and interactions with dietary n-3 fatty acids in 
an Alaska Native (Yup'ik) population. Metabolism 64: 689-697, 
2015.
MOLECULAR MEDICINE REPORTS  16:  3947-3957,  2017 3957
24. Liang J, Pei XR, Zhang ZF, Wang N, Wang JB and Li Y: A chronic 
oral toxicity study of marine collagen peptides preparation from 
chum salmon (Oncorhynchus keta) skin using Sprague-Dawley 
rat. Mar Drugs 10: 20-34, 2012.
25. Wang P, Xu TY, Guan YF, Tian WW, Viollet B, Rui YC, Zhai QW, 
Su DF and Miao CY: Nicotinamide phosphoribosyltransferase 
protects against ischemic stroke through SIRT1-dependent 
adenosine monophosphate-activated kinase pathway. Ann 
Neurol 69: 360-374, 2011.
26. Abid Hussein MN, Meesters EW, Osmanovic N, Romijn FP, 
Nieuwland R and Sturk A: Antigenic characterization of endo-
thelial cell-derived microparticles and their detection ex vivo. 
J Thromb Haemost 1: 2434-2443, 2003.
27. Wang P, Xu TY, Wei K, Guan YF, Wang X, Xu H, Su DF, Pei G 
and Miao CY: ARRB1/β-arrestin-1 mediates neuroprotection 
through coordination of BECN1-dependent autophagy in cere-
bral ischemia. Autophagy 10: 1535-1548, 2014.
28. Wang P, Du H, Zhou CC, Song J, Liu X, Cao X, Mehta JL, Shi Y, 
Su DF and Miao CY: Intracellular NAMPT-NAD+-SIRT1 
cascade improves post-ischaemic vascular repair by modulating 
Notch signalling in endothelial progenitors. Cardiovasc Res 104: 
477-488, 2014.
29. Wang P, Xu TY, Guan YF, Su DF, Fan GR and Miao CY: 
Perivascular adipose tissue-derived visfatin is a vascular smooth 
muscle cell growth factor: Role of nicotinamide mononucleotide. 
Cardiovasc Res 81: 370-380, 2009.
30. Livak KJ and Schmittgen TD: Analysis of relative gene expres-
sion data using real-time quantitative PCR and the 2(-Delta Delta 
C(T)) method. Methods 25: 402-408, 2001.
31. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, 
Williams DE and Geiss L: Changes in diabetes-related compli-
cations in the United States, 1990-2010. N Engl J Med 370: 
1514-1523, 2014.
32. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, 
Nauck M, Peters AL, Tsapas A, Wender R and Matthews DR: 
Management of hyperglycemia in type 2 diabetes, 2015: A 
patient-centered approach: Update to a position statement of the 
American diabetes association and the European association for 
the study of diabetes. Diabetes Care 38: 140-149, 2015.
33. Mori TA, Watts GF, Burke V, Hilme E, Puddey IB and Beilin LJ: 
Differential effects of eicosapentaenoic acid and docosahexae-
noic acid on vascular reactivity of the forearm microcirculation 
in hyperlipidemic, overweight men. Circulation 102: 1264-1269, 
2000.
34. White PJ, Mitchell PL, Schwab M, Trottier J, Kang JX, 
Barbier O and Marette A: Transgenic ω‑3 PUFA enrichment 
alters morphology and gene expression profile in adipose tissue 
of obese mice: Potential role for protectins. Metabolism 64: 
666-676, 2015.
35. Osanai T, Tanaka M, Magota K, Tomita H and Okumura K: 
Coupling factor 6-induced activation of ecto-F1F(o) 
complex induces insulin resistance, mild glucose intolerance 
and elevated blood pressure in mice. Diabetologia 55: 520-529, 
2012.
36. Wang L, An X, Yang F, Xin Z, Zhao L and Hu Q: Isolation and 
characterisation of collagens from the skin, scale and bone of 
deep‑sea redfish (Sebastes mentella). Food Chem 108: 616‑623, 
2008.
37. Osanai T, Tanaka M, Kamada T, Nakano T, Takahashi K, Okada S, 
Sirato K, Magota K, Kodama S and Okumura K: Mitochondrial 
coupling factor 6 as a potent endogenous vasoconstrictor. J Clin 
Invest 108: 1023-1030, 2001.
38. Li XL, Xing QC, Dong B, Gao YY, Xing SS, Pang YZ, Jiang HF 
and Tang CS: Plasma level of mitochondrial coupling factor 
6 increases in patients with type 2 diabetes mellitus. Int J 
Cardiol 117: 411-412, 2007.
39. Yuana Y, Bertina RM and Osanto S: Pre-analytical and 
analytical issues in the analysis of blood microparticles. Thromb 
Haemost 105: 396-408, 2011.
40. Tsimerman G, Roguin A, Bachar A, Melamed E, Brenner B and 
Aharon A: Involvement of microparticles in diabetic vascular 
complications. Thromb Haemost 106: 310-321, 2011.
41. Werner N, Wassmann S, Ahlers P, Kosiol S and Nickenig G: 
Circulating CD31+/annexin V+ apoptotic microparticles 
correlate with coronary endothelial function in patients with 
coronary artery disease. Arterioscler Thromb Vasc Biol 26: 
112-116, 2006.
42. Aneiros A and Garateix A: Bioactive peptides from marine 
sources: Pharmacological properties and isolation procedures. 
J Chromatogr B Analyt Technol Biomed Life Sci 803: 41-53, 
2004.
43. He Y, Yang J, Li H, Shao H, Wei C, Wang Y, Li M and Xu C: 
Exogenous spermine ameliorates high glucose-induced cardio-
myocytic apoptosis via decreasing reactive oxygen species 
accumulation through inhibiting p38/JNK and JAK2 pathways. 
Int J Clin Exp Pathol 8: 15537-15549, 2015.
44. Duan SZ, Ivashchenko CY, Usher MG and Mortensen RM: 
PPAR-gamma in the cardiovascular system. PPAR Res 2008: 
745804, 2008.
45. Panunti B and Fonseca V: Effects of PPAR gamma agonists on 
cardiovascular function in obese, non-diabetic patients. Vascul 
Pharmacol 45: 29-35, 2006.
